Get the Stockscreener App
118.73
0.64%
0.75
After Hours:
117.40
-1.33
-1.12%
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $118.73, with a volume of 5.39M.
It is up +0.64% in the last 24 hours and up +9.71% over the past month.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$117.98
Open:
$118.57
24h Volume:
5.39M
Relative Volume:
0.77
Market Cap:
$147.32B
Revenue:
$28.80B
Net Income/Loss:
$6.31B
P/E Ratio:
23.65
EPS:
5.02
Net Cash Flow:
$9.37B
1W Performance:
-1.17%
1M Performance:
+9.71%
6M Performance:
+7.91%
1Y Performance:
+58.84%
1-Day Range:
$118.46
$120.89
1-Week Range:
$117.07
$120.89
52-Week Range:
$74.80
$121.83
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
118.73 | 146.40B | 28.80B | 6.31B | 9.37B | 5.02 |
|
LLY
Lilly Eli Co
|
705.44 | 625.77B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.84 | 424.47B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
209.15 | 364.92B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
127.25 | 240.07B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.66 | 210.36B | 63.43B | 16.42B | 14.72B | 6.49 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-25 | Upgrade | Truist | Hold → Buy |
| Jul-25-25 | Upgrade | Needham | Hold → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Exclusive: CVS holds off adding Gilead’s new HIV prevention shot to drug coverage lists - Reuters
Exclusive-CVS holds off adding Gilead’s new HIV prevention shot to drug coverage lists By Reuters - Investing.com
Gilead Sciences to Present at Upcoming Investor Conferences - Business Wire
Goldman Sachs Reiterates a Hold Rating on Gilead Sciences (GILD) - MSN
Stock Analysis | Gilead Sciences OutlookTechnical Momentum Gathers, But Earnings May Determine Short-Term Fate - AInvest
Ligand to Participate in September Investor Conferences - GlobeNewswire Inc.
We are positive on Gilead Sciences' base business growth: Meacham - BNN Bloomberg
Gilead attacks remdesivir patent of Chinese research institute at UPC - JUVE Patent
Insider Selling at Gilead Sciences: A Signal of Liquidity or a Cautionary Tale? - AInvest
Mizuho Securities Keeps Buy Rating on Gilead Sciences with $131 Target - AInvest
Exas, Guardant, Gilead among gainers as Supreme Court ensures free preventive care - MSN
Gilead Sciences CCO Mercier sells $3.3m in shares - Investing.com
Gilead Sciences Inc. Stock Recovery Path — Analyst BreakdownJuly 2025 Outlook & Community Verified Swing Trade Signals - beatles.ru
Gilead Sciences CFO sells $296k in shares - Investing.com
GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait? - Nasdaq
Sure, Biogen (BIIB) Has Been on a Hot Streak Recently But My Bet’s on Gilead Sciences (GILD) - Money Morning
Argus Adjusts Price Target on Gilead Sciences to $130 From $120 - MarketScreener
Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use - PMLiVE
Gilead Sciences stock price target raised to $131 from $117 at Mizuho - Investing.com Canada
Mizuho Adjusts Price Target on Gilead Sciences to $131 From $117, Maintains Outperform Rating - MarketScreener
Gilead Sciences' Outperformance Means Overvalued (NASDAQ:GILD) - Seeking Alpha
Short Covering May Lift Gilead Sciences Inc. in Near TermJuly 2025 Patterns & Weekly High Return Forecasts - metal.it
What makes Gilead Sciences Inc. stock attractive todayJuly 2025 Review & Fast Moving Market Watchlists - thegnnews.com
Gilead upgraded to Buy at Needham on new HIV drug - MSN
Gilead Sciences Stock Surges in Trading Volume to 96th Rank Amid 0.55% Drop and Insider Sales - AInvest
Gilead Sciences Appoints New Senior Vice President - The Globe and Mail
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now? - MSN
Gilead Sciences and the Pricing Strategy of Lenacapavir: Balancing Profit and Public Health in the Fight Against HIV - AInvest
Gilead Sciences CEO Says HIV Prevention Drug Offers Clear Value - Bloomberg.com
Gilead Sciences' Triple Negative Breast Cancer Study: A Potential Game-Changer for the Oncology Sector - AInvest
Gilead Sciences Sees Decline in Short Interest, Market Sentiment Remains Unclear - AInvest
Gilead Sciences (GILD) Appoints New Senior Vice President and Pr - GuruFocus
Cantor Fitzgerald Keeps Their Buy Rating on Gilead Sciences (GILD) - The Globe and Mail
Drawing Inspiration from Nature: Olivier Nolan-Stevaux’s Work in Oncology Research - Gilead Sciences
Gilead Sciences' Profit Outlook: Beyond the Numbers - AInvest
We Think Gilead Sciences' (NASDAQ:GILD) Profit Is Only A Baseline For What They Can Achieve - Yahoo Finance
Gilead to buy Nimbus Therapeutics' NASH programme for up to $1.2 billion - FirstWord Pharma
Q2 Rundown: Gilead Sciences (NASDAQ:GILD) Vs Other Therapeutics Stocks - Yahoo Finance
Gilead Sciences’s Q2 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Gilead, J&J Pare Case on Laurus Copy of HIV Drug to Two Patents - Bloomberg Law News
Gilead stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com
Gilead Sciences' Q2 Earnings Call: Growth, Strategic Advances, and Positive Outlook - AInvest
Gilead Sciences' Sacituzumab Govitecan: A Promising New Lung Cancer Treatment - AInvest
Message from the General Manager - Gilead Sciences
Gilead Sciences stock hits 52-week high at 121.67 USD By Investing.com - Investing.com South Africa
Gilead Sciences stock hits 52-week high at 121.67 USD - Investing.com
Gilead Sciences: Strong Q2 Performance and Promising Yeztugo Launch Support Buy Rating - TipRanks
GILD Q2 Deep Dive: HIV Franchise Drives Growth, New Launches and Pipeline in Focus - Yahoo Finance
Gilead Sciences Receives Favorable CHMP Opinion for HIV Prevention Drug Lenacapavir - AInvest
Gilead Sciences’ Earnings Call Highlights Growth and Strategic Advances - TipRanks
Gilead Receives Favorable CHMP Opinion For HIV Prevention With Twice-Yearly Lenacapavir - Insider Monkey
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gilead Sciences Inc Stock (GILD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Commercial Officer |
Aug 15 '25 |
Sale |
118.53 |
28,000 |
3,318,927 |
114,168 |
| Dickinson Andrew D | Chief Financial Officer |
Aug 15 '25 |
Sale |
118.53 |
2,500 |
296,325 |
160,110 |
0.24%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):